Advertisements



Aerie Pharmaceuticals stock halted for FDA committee review of glaucoma treatment

Shares of Aerie Pharmaceuticals Inc. were halted for trading Friday, as the U.S. Food and Drugs Administration reviews a new drug application for .....»»

Category: topSource: marketwatchOct 13th, 2017

Spark Therapeutics shares halted as FDA committee reviews gene therapy treatment for eye disease

Spark Therapeutics Inc. shares were halted Thursday as a U.S. Food and Drugs Administration advisory committee meets to review the company's gene therapy treatment for patients with vision loss caused.....»»

Category: topSource: marketwatchOct 12th, 2017

Has Aerie Pharma Put The "Binary Boogeyman" To Bed With Roclatan Phase 3 Data?

Aerie Pharmaceuticals Inc (NASDAQ: AERI) shares were seen up over 29 percent Thursday after the company reported positive Phase III trial data on its glaucoma treatment can Latest Ratings for AERI DateFi.....»»

Category: blogSource: benzingaMay 25th, 2017

Aerie Pharma stock surges 32% on positive late-stage trial results for glaucoma eye drops

Aerie Pharmaceuticals Inc. shares surged as much as 32% in after hours trade Wednesday after the company said its eye drops intended for glaucoma had positive results in a late-stage clinical trial. If Aerie Pharma sees positive safe.....»»

Category: topSource: marketwatchMay 24th, 2017

Merrimack Pharmaceuticals" stock plummets after breast cancer treatment trial halted

Shares of Merrimack Pharmaceuticals Inc. plummeted 30% toward a three-year low in premarket trade Wednesday, after the company said it was halting .....»»

Category: topSource: marketwatchDec 21st, 2016

Regeneron"s stock halted as it receives FDA notice about arthritis treatment

Regeneron Pharmaceuticals Inc. said Friday that it and its partner Sanofi received notice from the Food and Drug Administration that the biologics license application for sarilumab won't be approved until certain concerns are resolved. The FDA's "comple.....»»

Category: topSource: marketwatchOct 28th, 2016

Regeneron"s Stock Halted As It Receives FDA Notice About Arthritis Treatment

Regeneron Pharmaceuticals Inc. said Friday that it and its partner Sanofi received notice from the Food and Drug Administration that the biologics license application for sarilumab won't be approved until certain concerns are resolved......»»

Category: topSource: foxnewsOct 28th, 2016

Aerie Pharmaceuticals Inc Stock May Soar to $96 Soon: RBC Capital

Industry experts contend that Aerie Pharmaceuticals Inc. (NASDAQ:AERI) stock valuation is too low, considering that the company boasts Roclatan, a blockbuster drug candidate for glaucoma. RBC Capital tends to agree with this proposition. In a research not.....»»

Category: topSource: bidnessetcSep 16th, 2016

Aerie Pharmaceuticals Stock May Soar to $96 Soon: RBC Capital

Industry experts contend that Aerie Pharmaceuticals Inc. (NASDAQ:AERI) stock valuation is too low, considering that the company boasts Roclatan, a blockbuster drug candidate for glaucoma. RBC Capital tends to agree with this proposition. In a research not.....»»

Category: topSource: bidnessetcSep 16th, 2016

Aerie Pharma announces secondary offering after big stock jump

Aerie Pharmaceuticals Inc. said late Thursday it was launching a secondary offering of its shares. Aerie shares surged 45% to close at $30.61 Thursday after the drug discovery company announced Wednesday its eye treatment Roclatan performed well in clini.....»»

Category: topSource: marketwatchSep 15th, 2016

Spectrum Pharmaceuticals" stock drops after cancer treatment voted down by FDA committee

Spectrum Pharmaceuticals Inc. said Wednesday that an Food and Drug Administration advisory committee voted that biotechnology company's cancer treatment, Qapzola, did not show substantial evidence of a treatment effect over placebo. The company said the .....»»

Category: topSource: marketwatchSep 14th, 2016

Aerie (AERI) Up on FDA Review Committee Result for Rhopressa

Zacks.....»»

Category: topSource: redinews16 hr. 5 min. ago

Aerie (AERI) Up on FDA Review Committee Result for Rhopressa

Shares of .....»»

Category: dealsSource: nytOct 17th, 2017

With nod from panel, Aerie inches toward FDA approval

Aerie Pharmaceuticals (Nasdaq: AERI) – which is in the process of building out its research and development team locally – is moving closer to U.S. Food and Drug Administration approval. On Friday, an FDA advisory committee voted in favor of .....»»

Category: topSource: bizjournalsOct 13th, 2017

Ethics report says NY lawmaker"s actions warrant review

The House Ethics Committee says it's extending its review of a congressman whose stock market trades prompted an advocacy group to request an investigation for possible violation of insider trading or conflict of interest laws......»»

Category: topSource: foxnewsOct 12th, 2017

Ethics panel extends review of New York GOP congressman

The House Ethics Committee says it's extending its review of a congressman whose stock market trades prompted an advocacy group to request an investigation for possible violation of insider trading or conflict of interest laws......»»

Category: topSource: foxnewsOct 12th, 2017

Ethics Committee extends review of New York congressman

The House Ethics Committee says it's extending its review of a congressman whose stock market trades prompted an advocacy group to request an investigation for possible violation of insider trading or conflict of interest laws......»»

Category: topSource: foxnewsOct 12th, 2017

Catabasis"s stock rockets after positive trial results of Duchenne muscular dystrophy treatment

Shares of Catabasis Pharmaceuticals Inc. rocketed 49% in premarket trade Wednesday, putting them on track to open at the highest level seen du.....»»

Category: topSource: marketwatchOct 4th, 2017

Are Options Traders Betting on a Big Move in Aerie (AERI) Stock?

Investors in Aerie Pharmaceuticals, Inc. (AERI) need to pay close attention to the stock based on moves in the options market lately. Investors in .....»»

Category: dealsSource: nytSep 13th, 2017

Adamas Pharma stock surges 7% after negative FDA decision for rival Acorda"s Parkinson"s treatment

Adamas Pharmaceuticals Inc. shares surged 6......»»

Category: topSource: marketwatchAug 29th, 2017

What"s in Store for Agios Pharma (AGIO) in Q2 Earnings?

Encouraging performance of Agios' (AGIO) lead candidate Idhifa, which is under review in the U.S. for treatment of AML might drive the stock in Q2. Agios Ph.....»»

Category: topSource: zacksJul 26th, 2017